Sangamo Therapeutics Inc. (Nasdaq: SGMO), a company involved in translating science into genomic therapies, announced on Friday that it has named Edward Rebar, PhD as its new senior vice president and chief technology officer, effective immediately.

Dr Rebar joined the company in 1998, and over the last 20 years he has led the development of its zinc finger protein platform. He has authored over 60 publications relating to the development of customised DNA binding proteins and nucleases for genome editing. Prior to joining Sangamo, he was a post-doctoral fellow at the University of California, Berkeley. He earned his BS in Biochemistry from Rutgers University and his PhD in Biophysics and Structural Biology from MIT.

Sandy Macrae, CEO of Sangamo, said, 'I'm very pleased to announce Ed Rebar's promotion to chief technology officer. During his tenure at Sangamo, Ed has led the development and optimisation of our core zinc finger technology. In the field of genome editing he is recognised as a leader and a strong voice for setting very high standards for editing technology being developed for therapeutic use.'